GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (STU:23I) » Definitions » Cyclically Adjusted PB Ratio

Intra-Cellular Therapies (STU:23I) Cyclically Adjusted PB Ratio : 8.34 (As of Sep. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Intra-Cellular Therapies Cyclically Adjusted PB Ratio?

As of today (2024-09-24), Intra-Cellular Therapies's current share price is €68.50. Intra-Cellular Therapies's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was €8.21. Intra-Cellular Therapies's Cyclically Adjusted PB Ratio for today is 8.34.

The historical rank and industry rank for Intra-Cellular Therapies's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:23I' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 5.87   Med: 7.73   Max: 9.36
Current: 9.03

During the past years, Intra-Cellular Therapies's highest Cyclically Adjusted PB Ratio was 9.36. The lowest was 5.87. And the median was 7.73.

STU:23I's Cyclically Adjusted PB Ratio is ranked worse than
92.42% of 567 companies
in the Drug Manufacturers industry
Industry Median: 1.79 vs STU:23I: 9.03

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Intra-Cellular Therapies's adjusted book value per share data for the three months ended in Jun. 2024 was €10.067. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €8.21 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Intra-Cellular Therapies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Intra-Cellular Therapies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Cyclically Adjusted PB Ratio Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 7.05 8.65

Intra-Cellular Therapies Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.88 6.35 8.65 8.21 7.97

Competitive Comparison of Intra-Cellular Therapies's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Cyclically Adjusted PB Ratio falls into.



Intra-Cellular Therapies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Intra-Cellular Therapies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=68.50/8.21
=8.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intra-Cellular Therapies's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Intra-Cellular Therapies's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=10.067/132.5538*132.5538
=10.067

Current CPI (Jun. 2024) = 132.5538.

Intra-Cellular Therapies Quarterly Data

Book Value per Share CPI Adj_Book
201409 3.538 100.428 4.670
201412 3.314 99.070 4.434
201503 5.876 99.621 7.818
201506 5.176 100.684 6.814
201509 10.396 100.392 13.727
201512 10.131 99.792 13.457
201603 9.404 100.470 12.407
201606 8.765 101.688 11.425
201609 8.223 101.861 10.701
201612 8.223 101.863 10.701
201703 7.603 102.862 9.798
201706 6.962 103.349 8.929
201709 6.171 104.136 7.855
201712 7.033 104.011 8.963
201803 6.275 105.290 7.900
201806 6.109 106.317 7.617
201809 5.539 106.507 6.894
201812 5.087 105.998 6.361
201903 4.633 107.251 5.726
201906 4.118 108.070 5.051
201909 3.729 108.329 4.563
201912 3.162 108.420 3.866
202003 5.884 108.902 7.162
202006 5.047 108.767 6.151
202009 7.515 109.815 9.071
202012 6.710 109.897 8.093
202103 6.338 111.754 7.518
202106 5.651 114.631 6.535
202109 5.084 115.734 5.823
202112 4.516 117.630 5.089
202203 7.656 121.301 8.366
202206 7.240 125.017 7.676
202209 7.310 125.227 7.738
202212 6.531 125.222 6.913
202303 6.127 127.348 6.377
202306 5.832 128.729 6.005
202309 5.849 129.860 5.970
202312 5.627 129.419 5.763
202403 5.658 131.776 5.691
202406 10.067 132.554 10.067

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Intra-Cellular Therapies  (STU:23I) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Intra-Cellular Therapies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies Headlines

No Headlines